Boehringer Ingelheim and Helsinn helped oncology vaccine developer Amal reach the second close of a series B round that now totals $32.7m.
Amal Therapeutics, a Switzerland-based biotechnology spinout from University of Geneva, extended a series B round co-led by pharmaceutical firms Boehringer Ingelheim and Helsinn to over €29m ($32.7m) on Monday.
Corporate venturing units Boehringer Ingelheim Venture Fund and Helsinn Investment Fund co-led the round with venture capital firm BioMedPartners, investing alongside High-Tech Gründerfonds (HTGF), VI Partners and Schroder Adveq, which forms part of investment manager Schroders.
The extension came in the form of a €21.2m second tranche that was added to…
